Navigation Links
Researcher of the University of Navarra discovered potential antidepressant compounds
Date:2/20/2008

This release is also available in Spanish.

Luis Berrade, a researcher with the Drug R&D Unit of the University of Navarra, has discovered new compounds with the potential for anti-depressant activity. All told, the chemist of the School of Sciences synthesized 51 compounds whose biological characteristics were evaluated by two of the most prestigious groups in this area: the Mediterranean Institute of Neurobiology, located in Italy, and the Department of Pharmacology of the University of Oslo.

The results obtained formed part of his doctoral dissertation, entitled Design, synthesis and preliminary biological evaluation of new derivatives of benzo[b]-thiophene in the Search for Agents for a New Anti-Depressant Therapy.

As the researcher explained, the new molecules which he designed affect two brain targets which are considered to be keys in the development of processes of depression. One of these is the serotonin transporter, whose reuptake reduction has already been shown to improve mood; the other is the serotoninergic receptor 5-HT7, a therapeutic target for serotonin whose modulation can provoke anti-depressant effects.

Trials in vivo

In order to study these two key targets, Luis Berrade developed chemical structures via the fusion of two similar chemical compounds: the benzo[b]-thiophene ring and arilamine. Following this, he compared the new compounds with a drug currently on the market, Fluoxetine. As a result of this research, he explained, we discovered that nine of these compounds demonstrated greater affinity, in this sense, than the commercial drug. As a consequence of this discovery, in January in vivo trials were begun in order to test their anti-depressant activity in mice.

This study, one of the first in the world in this specialty, was undertaken in collaboration with the Department of Pharmacology of the University of Navarra. Among its objectives was discovering whether these new compounds could reduce the minimum time required for anti-depressant drugs to ameliorate the symptoms of the disease: Currently, the time for an antidepressant to take effect is from three to six weeks, and this is an important factor in patient refusal to continue with these treatments; as a result it is very important to shorten the time required for the positive effects to appear.


'/>"/>

Contact: Oihane Lakar
oihane@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
5. Bipolar disorder relapses halved by Melbourne researchers
6. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
7. High and mighty: first common height gene identified by researchers behind obesity gene finding
8. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
9. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
10. Researchers develop long-lasting growth hormone
11. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 06, 2016 , ... For many years, Andrew G. Zubinas has ... The beauty of the Lithuanian language and its poetry inspired him in ... Zubinas lyrically explores all aspects of a living, breathing forest where nothing ever stays ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy ... through tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on the ... 26 people will be diagnosed with epilepsy within their lifetime. With such a ...
(Date:12/5/2016)... Reading, PA (PRWEB) , ... December 05, 2016 , ... ... partner in the United States and Canada for distribution of their natural fruits ... Hansen colors line is an exciting addition to our Life Sciences product portfolio,” ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Partners ("GPP") portfolio company, today announced it has acquired the assets of ... was previously a subsidiary of Chiltern International and focuses on clinical trial ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... The new ... the individual looking to buy neoprene knee sleeves for lifting and any ... design focuses heavily on two main aspects to provide a higher quality knee sleeve ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Eisai Inc. announced today new analyses and ... of the American Epilepsy Society (AES). ... adjunctive therapy for the treatment of partial onset seizures ... generalized tonic-clonic seizures (PGTC) in patients with epilepsy who ... Important Safety Information for FYCOMPA, including Boxed WARNING for ...
(Date:12/5/2016)... , Dec 5, 2016 Research and ... and Pregnancy Rapid Test Market Size, Share, Development, Growth and Demand ... ... The global female fertility and pregnancy rapid test market is ... global Female fertility and pregnancy rapid test market is witnessing high ...
(Date:12/5/2016)... AVIV, Israel , December 5, 2016 ... to identifying, in-licensing and developing promising therapeutic candidates, presents positive ... for BL-8040, the Company,s leading oncology platform at the ongoing ... in San Diego, California . ... , , ...
Breaking Medicine Technology: